Israeli bio-pharmaceutical company Kadimastem, recently developed a cell therapy for Amyotrophic lateral sclerosis (ALS) that was successful in its first human clinical trial. ALS is a progressive nervous system disease that causes loss of muscle control. Currently, there is no cure, however the cell therapy designed by Kadimastem has the capacity to halt the condition for a period of three months.
The therapy is based on brain-supporting stem cells that replace non-functional cells to combat the disease. In the company’s next clinical trial, the aim is to transform ALS from a lethal disease to a chronic disease that will allow for the survival of patients. By manufacturing stem cells, the company is working to restore brain functionality by supporting neurons in the brain and spinal cord.
Kadimastem researchers are also developing a self-therapy to cure diabetes. The solution will take the form of a small device inserted under the skin to detect glucose levels and release the proportionate amount of insulin. Although Kadimastem’s technology was successfully tested on mice, it is expected to take five to seven years before the solution is available for human use.